BELINOSTAT: A HISTONE DEACETYLASE INHIBITOR FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAAbstract
Histone deacetylase inhibitors (HDACIs) are a group of agents that have exhibited antitumor activity in vivo and in vitro, directing to clinical trials estimating their efficacy in multiple cancer types. Belinostat is under global development with Spectrum Pharmaceuticals, currently approved by the U.S. Food and Drug Administration with indications for relapsed or refractory peripheral T-cell lymphoma on July 2014 and is under regulatory review in the Europe. Belinostat has been investigated as a single agent and in groups with further chemotherapies and biological agents, in the management of solid tumors and lymphoma. The main side effects are pyrexia, pneumonia, anemia, thrombocytopenia, neutropenia and fatigue, which are manageable. Belinostat is also being investigated in patients with bladder cancer, prostate cancer, solid tumor, mantle cell lymphoma, refractory advanced thymic epithelial tumors, pancreatic cancer and ovarian cancer. This article reviews the obtainable information on Belinostat with respect to its clinical pharmacology, mechanism of action, pharmacodynamics, pharmacokinetics, metabolism, preclinical studies and clinical trials.
A. Verma, M. Porwal *, A. Kumar, V. Rastogi, N. Verma, A. K. Mishra and K. K. Maheshwari
Faculty of Pharmacy, IFTM University, Lodhipur-Rajput, Moradabad, Uttar Pradesh, India
24 May, 2016
09 August, 2016
28 September, 2016
01 November, 2016